SCHEMBL4590153

SCHEMBL4590153

COc1cccc(C)c1C1(O)C(=O)Nc2ccc(Cl)cc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.50
CBX7 O95931 1/20 0.48
CDYL Q9Y232 1/20 0.48
IDO1 P14902 2/20 0.45
BRD4 O60885 3/20 0.43
MEN1 O00255 1/20 0.43
GAA P10253 2/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
ALOX12 P18054 1/20 0.42
MMP2 P08253 1/20 0.41
MMP3 P08254 1/20 0.41
MMP8 P22894 1/20 0.41
MMP14 P50281 1/20 0.41
MMP17 Q9ULZ9 1/20 0.41
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KCNQ3 O43525 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2493174 0.92 KMT2A (0.55) KMT2ACBX7CDYLIDO1BRD4
SCHEMBL4589436 0.85 KMT2A (0.51) KMT2ABRD4GAAKDM4EALDH1A1
SCHEMBL4589642 0.84 CBX7 (0.44) KMT2ACBX7CDYLIDO1MEN1
SCHEMBL1464565 0.84 KMT2A (0.72) KMT2ACBX7CDYLIDO1MEN1
SCHEMBL4590131 0.83 KMT2A (0.56) KMT2ACBX7CDYLIDO1BRD4
SCHEMBL2495396 0.83 CBX7 (0.48) KMT2ACBX7CDYLIDO1BRD4
SCHEMBL2495393 0.82 KMT2A (0.57) KMT2ACBX7CDYLIDO1BRD4
SCHEMBL1465397 0.81 KMT2A (0.48) KMT2ACBX7CDYLIDO1BRD4
SCHEMBL2497474 0.79 BRD4 (0.57) KMT2ACBX7CDYLIDO1BRD4
SCHEMBL2497604 0.79 KMT2A (0.51) KMT2ACBX7CDYLIDO1BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7425566-B2 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them SANOFI-AVENTIS (FR) 2008-09-16 US disclosed
US-20050176770-A1 Novel 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them SANOFI-AVENTIS (FR) 2005-08-11 US disclosed
US-6864277-B2 1,3-dihydro-2H-indol-2-one derivatives, method for preparing same and pharmaceutical compositions containing them SANOFI-SYNTHELABO (FR) 2005-03-08 US disclosed
EP-1296976-B1 NOVEL 1,3-DIHYDRO-2H-INDOL-ONE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SANOFI AVENTIS (FR) 2005-01-26 EP disclosed
US-20030162767-A1 With affinity for and selectivity towards the V1b receptors or both the V1b and V1a receptors of arginine-vasopressin SANOFI-AVENTIS (FR) 2003-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162767-A1 With affinity for and selectivity towards the V1b receptors or both the V1b and V1a receptors of arginine-vasopressin AVPR1B, AVPR1A, AVPR2 KMT2A 4115/4885CBX7 4049/4885CDYL 4544/4885
US-20050176770-A1 Novel 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them AVPR1B, AVPR2, AVPR1A KMT2A 3798/4885CBX7 3930/4885CDYL 3213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.